Thorwarth M, Schultze-Mosgau S, Wehrhan F, Srour S, Wiltfang J, Neukam FW, et al
Common injection sites include the abdomen (at least two inches away from the navel) or the outer thigh
Unlike semaglutide which targets a single GLP-1 receptor, Retatrutide activates GIP, GLP-1, and glucagon receptors simultaneously, producing significantly greater metabolic effects in research models
Track Body Composition, Not Just Weight If you are on a GLP-1 medication, I strongly recommend tracking body composition rather than relying solely on the scale
Notably, 86% of semaglutide recipients achieved at least 5% weight loss, and 50% achieved at least 15% weight lossthresholds widely recognized as clinically significant
The reversibility of gastroparesis symptoms associated with Ozempic use is a significant concern for both patients and healthcare professionals